Magnetic Resonance Image-Guided Biopsies with a High Detection Rate of Prostate Cancer

Engehausen, Dirk G.; Engelhard, Karl; Schwab, Siegfried A.; Uder, Michael; Wach, Sven; Wullich, Bernd; Krause, Fabian

doi:10.1100/2012/975971

Cited by 20 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are comparable to the results of Engehausen et al [14]. In the latter study, 10.4 % of cancers were missed using MRGB, assuming that these carcinomas were already present at the time of MRI intervention and were not de novo neoplasias [14]. The follow-up period was three years in our study.…”

supporting

confidence: 91%

“…Hence, the detection rate for clinically significant cancer in our study is 100 %. This is in accordance with and even higher than observed in the review of the literature [12,14,15,18,19,29]. This emphasizes the capability of MRGB to diagnose clinically significant cancer in patients after negative TRUS.…”

supporting

confidence: 90%

“…The rate of missed cancer in MRGB studies is reported at 6 % in a paper published by Hoeks et al, with a mean follow-up of only five months [15]. These data are comparable to the results of Engehausen et al [14]. In the latter study, 10.4 % of cancers were missed using MRGB, assuming that these carcinomas were already present at the time of MRI intervention and were not de novo neoplasias [14].…”

supporting

confidence: 60%

See 2 more Smart Citations

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Polanec

Helbich

Margreiter

et al. 2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

!Objectives: To evaluate the detection rate of prostate cancer (PCa) after magnetic resonance-guided biopsy (MRGB); to monitor the patient cohort with negative MRGB results and to compare our own results with other reports in the current literature. Materials and Methods: A group of 41 patients was included in this IRB-approved study and subjected to combined MRI and MRGB. MRGB was performed in a closed 1.5 T MR unit and the needle was inserted rectally. The follow-up period ranged between 12 and 62 months (mean 3.1 years). To compare the results with the literature, a systematic literature search was performed. Eighteen publications were evaluated. Results: The cancer-suspicious regions were punctured successfully in all cases. PCa was detected in eleven patients (26.9 %) who were all clinically significant. MRGB showed a benign histology in the remaining 30 patients. In the followup (mean 3.1 years) of patients with benign histology, no new PCa was diagnosed. The missed cancer rate during follow-up was 0.0 % in our study. Conclusion: MRGB is effective for the detection of clinically significant cancer, and this is in accordance with the recent literature. In the follow-up of patients with benign histology, no new PCa was discovered. Although the probability of developing PCa after negative MRGB is very low, active surveillance is reasonable.

show abstract

supporting

confidence: 91%

supporting

confidence: 90%

supporting

confidence: 60%

See 1 more Smart Citation

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Polanec

Helbich

Margreiter

et al. 2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

show abstract

“…Another out-of-bore approach uses the MR imaging in a cognitive manner, with the operator interpreting the previously acquired MR imaging information either as reported or by direct visualization and then performing a transrectal US sampling directed to the cognitively recalled locations (28). The transrectal MR imaging-guided biopsy studies (32)(33)(34)(35)(36)(37)(38)(39)(40) report cancer positivity rates of 8%-59%. Puech et al (41) compared cognitive and fusion techniques, showing no significant differences in biopsy yield.…”

Section: Discussionmentioning

confidence: 99%

Transperineal In-Bore 3-T MR Imaging–guided Prostate Biopsy: A Prospective Clinical Observational Study

Penzkofer¹,

Tuncalı²,

Fedorov³

et al. 2015

Radiology

View full text Add to dashboard Cite

The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.q RSNA, 2014 Purpose:To determine the detection rate, clinical relevance, Gleason grade, and location of prostate cancer (PCa) diagnosed with and the safety of an in-bore transperineal 3-T magnetic resonance (MR) imaging-guided prostate biopsy in a clinically heterogeneous patient population. Materials and Methods:This prospective retrospectively analyzed study was HIPAA compliant and institutional review board approved, and informed consent was obtained. Eighty-seven men (mean age, 66.2 years 6 6.9) underwent multiparametric endorectal prostate MR imaging at 3 T and transperineal MR imaging-guided biopsy. Three subgroups of patients with at least one lesion suspicious for cancer were included: men with no prior PCa diagnosis, men with PCa who were undergoing active surveillance, and men with treated PCa and suspected recurrence. Exclusion criteria were prior prostatectomy and/or contraindication to 3-T MR imaging. The transperineal MR imaging-guided biopsy was performed in a 70-cm wide-bore 3-T device. Overall patient biopsy outcomes, cancer detection rates, Gleason grade, and location for each subgroup were evaluated and statistically compared by using x 2 and one-way analysis of variance followed by Tukey honestly significant difference post hoc comparisons. Results:Ninety biopsy procedures were performed with no serious adverse events, with a mean of 3.7 targets sampled per gland. Cancer was detected in 51 (56.7%) men: 48.1% (25 of 52) with no prior PCa, 61.5% (eight of 13) under active surveillance, and 72.0% (18 of 25) in whom recurrence was suspected. Gleason pattern 4 or higher was diagnosed in 78.1% (25 of 32) in the no prior PCa and active surveillance groups. Gleason scores were not assigned in the suspected recurrence group. MR targets located in the anterior prostate had the highest cancer yield (40 of 64, 62.5%) compared with those for the other parts of the prostate (P , .001). Conclusion:In-bore 3-T transperineal MR imaging-guided biopsy, with a mean of 3.7 targets per gland, allowed detection of many clinically relevant cancers, many of which were located anteriorly.q RSNA, 2014

show abstract

“…Selected studies have found higher rates of cancer detection with MRI‐guided biopsy than with TRUS‐guided biopsy . Nevertheless, when Moore et al .…”

Section: Applications Of Mri In the Detection Of Prostate Cancermentioning

confidence: 99%

Role of MRI in prostate cancer detection

Shukla–Dave

Hricak

2013

NMR in Biomedicine

View full text Add to dashboard Cite

The standard approach for the detection of prostate cancer--prostate-specific antigen (PSA) screening followed by transrectal ultrasonography (TRUS)-guided biopsy--has low sensitivity and provides limited information about the true extent and aggressiveness of the cancer. Improved methods are needed to assess the extent and aggressiveness of the cancer and to identify patients who will benefit from therapy. In recent years, there has been tremendous development of acquisition and processing tools for physiological and metabolic MRI techniques which play a potential role in the detection, localization and characterization of prostate cancer, such as dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted MRI (DW-MRI) and/or proton MR spectroscopic imaging ((1)H MRSI). The standard protocol for prostate MRI without the use of a contrast agent involves multi-planar T1 -weighted MRI, T2 -weighted MRI and DW-MRI. This review discusses the potential role of MRI in the detection of prostate cancer, specifically describing the status of MRI as a tool for guiding targeted prostate biopsies and for detecting cancer in the untreated and treated gland. In addition, future areas of MRI research are briefly discussed. Groups conducting clinical trials should consider the recommendations put forward by the European Consensus Meeting, which state that the minimum requirements for prostate MRI are T1 -weighted MRI, T2 -weighted MRI, DCE-MRI (which involves the use of a contrast agent) and DW-MRI with a pelvic phased-array coil and propose the use of transperineal template mapping biopsies as the optimal reference standard.

show abstract

Magnetic Resonance Image-Guided Biopsies with a High Detection Rate of Prostate Cancer

Cited by 20 publications

References 25 publications

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Transperineal In-Bore 3-T MR Imaging–guided Prostate Biopsy: A Prospective Clinical Observational Study

Role of MRI in prostate cancer detection

Contact Info

Product

Resources

About